𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Salvage therapy for primary central nervous system lymphoma with90Y-Ibritumomab and Temozolomide

✍ Scribed by Vincenzo Pitini; Sergio Baldari; Giuseppe Altavilla; Carmela Arrigo; Claudia Naro; Francesca Perniciaro

Publisher
Springer US
Year
2007
Tongue
English
Weight
169 KB
Volume
83
Category
Article
ISSN
0167-594X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Study of radiolabeled indium-111 and ytt
Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma
✍ Fabio M. Iwamoto; Jazmin Schwartz; Neeta Pandit-Taskar; Scott Peak; Chaitanya R. πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 205 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Therapeutic options for refractory or recurrent primary central nervous system lymphoma (PCNSL) are limited. The blood–brain barrier makes many agents used in systemic lymphomas ineffective in CNS lymphomas. The objective of this study was to determine whether intravenou

Immunochemotherapy with rituximab and te
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas
✍ Eric T. Wong; Roy Tishler; Loretta Barron; Julian K. Wu πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 172 KB

## Abstract ## BACKGROUND Methotrexate‐based and alkylator‐based chemotherapy regimens are associated with renal and bone marrow toxicities, which limit their use in patients with central nervous system (CNS) lymphomas. The authors report their experience with an immunochemotherapy regimen consist